<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823004</url>
  </required_header>
  <id_info>
    <org_study_id>1969yazdRCCI</org_study_id>
    <nct_id>NCT00823004</nct_id>
  </id_info>
  <brief_title>Antagonist/Letrozole in Poor Responders</brief_title>
  <official_title>GnRH Antagonist /Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yazd Research &amp; Clinical Center for Infertility</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yazd Research &amp; Clinical Center for Infertility</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in
      assisted reproduction and there is no consensus on the ovarian stimulation choice regime for
      poor responders.

      Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare (MF) and a GnRH
      antagonist/letrozole (A/L) protocols in poor responders undergoing in vitro fertilization
      (IVF).

      Methods: One hundred eighty poor responder patients will be randomized to an ovarian
      stimulation protocol with either a MF or a letrozole and high dose FSH/hMG and flexible GnRH
      antagonist protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All women receive 21 days of an oral contraceptive. A MF protocol will be used for ovarian
      stimulation in 90 patients. Three days after the last pill, a GnRH-agonist buserelin
      (Suprefact, Aventis Pharma, Frankfurt, Germany) 50 µg SC twice daily will be initiated and
      two days after that, recombinant FSH (Gonal-F, Serono, Aubonne, Switzerland) or hMG
      (Merional, IBSA, Lugano, Switzerland) 300-450 IU/day will be administered. Ninetyty patients
      will be assigned to an A/L protocol. After oral contraceptive withdrawal bleeding on day 3 of
      cycle, recombinant FSH or hMG 300-450 IU/day will be initiated and letrozole (Femara,
      Novartis, East Hanover, NJ) 5 mg/day will be administered for 5 days. When the dominant
      follicle reached 14 mm in mean diameter, ganirelix acetate (Antagon, Organon, West Orange,
      NJ) 0.25 mg SC daily will be started.

      Patients weill be monitored by serial vaginal ultrasonography and measurement of serum E2
      level. When at least two follicles with a mean diameter of 18 mm will be achieved hCG
      (Pregnyl, Organon, Oss, the Netherlands) 10000 IU will be administered. Cycle cancellation
      will be considered when fewer than two follicles with normal growth pattern weill be noted.

      Oocyte retrieval will be performed 34-36 hours after hCG administration. Conventional IVF or
      intracytoplasmic sperm injection (ICSI) will be performed as appropriate. Embryos with 4-6
      equally sized blastomers on day 2 with ≤ 20% fragmentation and no multinucleation will be
      considered top quality embryos. Embryos with 2-6 equally or unequally blastomers with ≤20%
      fragmentation and no multinucleation will be considered good quality embryos. Embryos will be
      transferred on day 2 or 3 under ultrasound guidance, with a C.C.D. embryo transfer catheter (
      Laboratoire C.C.D., Paris, France). Luteal support with progesterone in oil (Progesterone,
      Aburaihan Co., Tehran, Iran) 100 mg daily IM will be started on the day of oocyte retrieval.

      Serum β-hCG level will be measured 14 days after embryo transfer and a transvaginal
      ultrasonography will be performed 3 weeks after positive β-hCG for documentation of
      gestational sac and fetal heart activity. Clinical pregnancy will be considered as the
      presence of a gestational sac with fetal heart activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>stimulation outcomes</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>letrozole 5mg/day from day 3 to day 7 of menstrual cycle</description>
    <arm_group_label>1</arm_group_label>
    <other_name>letrozole (Femara, Novartis, East Hanover, NJ)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive (Marvelone)</intervention_name>
    <description>oral contraceptive, first 21 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Marvelon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist (buserelin)</intervention_name>
    <description>50 µg SC twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>suprefact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH or hMG</intervention_name>
    <description>recombinant FSH or hMG 300-450 IU/day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Gonal F</other_name>
    <other_name>Merional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganirelix acetate</intervention_name>
    <description>GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Antagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one previous failed IVF cycle in which three or fewer follicles with a mean
             diameter of 16 mm were achieved, and/or

          -  serum E2 level measured on the day of hCG administration was ≤500 pg/ml

        Exclusion Criteria:

          -  day 3 serum FSH level ≥12 mIU/mL

          -  there is no age limit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>homa oskouian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research and clinical center for infertility</affiliation>
  </overall_official>
  <overall_official>
    <last_name>robab davar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research and clinical center for infertility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research and clinical center for infertility</name>
      <address>
        <city>Yazd</city>
        <zip>8916877391</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>December 20, 2013</last_update_submitted>
  <last_update_submitted_qc>December 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yazd Research &amp; Clinical Center for Infertility</investigator_affiliation>
    <investigator_full_name>homa oskouian</investigator_full_name>
    <investigator_title>fellowship</investigator_title>
  </responsible_party>
  <keyword>controlled ovarian hyperstimulation</keyword>
  <keyword>pregnancy rate</keyword>
  <keyword>Poor responders</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>letrozole</keyword>
  <keyword>in vitro fertilization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

